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6158 | Chem. Sci., 2015, 6, 6158–6164st sugars: a chemical synthesis of
heparin-related [4]n oligosaccharides from 16-mer
to 40-mer†
Steen U. Hansen,‡a Gavin J. Miller,‡a Matthew J. Cliﬀ,b Gordon C. Jaysonc
and John M. Gardiner*a
The chemical synthesis of long oligosaccharides remains a major challenge. In particular, the synthesis of
glycosaminoglycan (GAG) oligosaccharides belonging to the heparin and heparan sulfate (H/HS) family
has been a high proﬁle target, particularly with respect to the longer heparanome. Herein we describe a
synthesis of the longest heparin-related oligosaccharide to date and concurrently provide an entry to the
longest synthetic oligosaccharides of any type yet reported. Speciﬁcally, the iterative construction of a
series of [4]n-mer heparin-backbone oligosaccharides ranging from 16-mer through to the 40-mer in
length is described. This demonstrates for the ﬁrst time the viability of generating long sequence
heparanoids by chemical synthesis, via practical solution-phase synthesis. Pure-Shift HSQC NMR
provides a dramatic improvement in anomeric signal resolution, allowing full resolution of all 12
anomeric protons and extrapolation to support anomeric integrity of the longer species. A chemically
pure 6-O-desfulfated GlcNS-IdoAS icosasaccharide (20-mer) represents the longest pure synthetic
heparin-like oligosaccharide.Introduction
The synthesis of long sequence oligosaccharides ($10 mono-
saccharide units) is an area of enduring challenge for synthetic
carbohydrate chemistry across a diversity of oligosaccharide
types. Despite advances in synthetic methods and recent prog-
ress in supported and automated chemistry,1–5 access to longer
oligosaccharides remains highly demanding in both synthetic
input and in characterization.
Heparin and heparan sulfate (H/HS) are highly polydisperse
examples of glycosaminoglycan (GAG) saccharides, structurally
characterized by alternating 1 / 4-linked D-glucosamine and
uronic acid units, the latter constituting either D-glucuronic or L-
iduronic acid. H/HS typically occurs in oligomers up to 40–50
units in length and though native oligomers range to >150 in
length, most biological recognition relates to shorter oligomers,
spanning the 6–40-mer range. Additionally, the backbone is
modied by a variety of diﬀerent sulfation patterns, mostlynd School of Chemistry, University of
UK. E-mail: gardiner@manchester.ac.uk;
Faculty of Life Sciences, The University of
r M1 7DN, UK
anchester, Manchester, UK
tion (ESI) available. See DOI:involving the 2-amino and O6 of D-GlcN and the O2 of the uronic
acid, with rarer D-GlcN O3 sulfation, and are organized into low-
and high-sulfation domains with heparin typied by higher
iduronate content and sulfation than heparan sulfate. These
oligosaccharides are known to bind to over one hundred
proteins and play many diverse regulatory roles in biology,
including angiogenesis, inammation, stem-cell diﬀerentia-
tion, pathogen infectivity and are also essentially involved
in chemokine biology, regulating oligomerization dynamics
and cell-migration properties.6–8 There is considerable
interest in the potential to dene therapeutically-viable H/HS
sequences,9,10 underscored by the development of Arixtra (Fon-
daparinux) as a synthetic anti-coagulant heparin fragment,11,12
and advances in biocatalytic access to longer sequence
replacements for medicinal heparin.13,14
The diverse structural microheterogeneity of the natural
oligosaccharides and these pervasive regulatory roles ensure
that dening the eﬀects of specic structural diﬀerences on
binding and biological eﬀects of H/HS sequences remains at
the forefront of carbohydrate chemical biology, whilst also
amongst the most structurally-diverse and functionally-
complex of oligosaccharide targets. There is considerable
evidence that native H/HS oligosaccharides interact with
various heparin-binding proteins across a wide range of olig-
omer lengths. Recent structural work has shown that even
H/HS disaccharides can provide binding selectivity for the
important growth factors FGF1 15 and FGF2,16 however,
sequences of 8–12 monosaccharides are established asThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineessential lengths for many HS-mediated biological eﬀects.
Protein binding selectivity does not necessarily correlate to
observed biological eﬀects, which involve more complex
processes of assembling HS ligand–protein–receptor
complexes, including in some cases essential dimerization, to
eﬀect biological signaling. The nature of the uronic acid resi-
dues is established as central to biological roles,17 and there is
good evidence of biological eﬀects of sulfation levels of GlcN
O6.18 With respect to structurally-pure synthetic GAGs, prior
work has indicated that homogenous sulfation levels and
locations can also aﬀect the binding preferences of other GAGs
to target proteins19–21 and there is importance in revealing
evidence for diﬀerential in vitro and in vivo biological conse-
quences of changes in sulfation locations.13
Synthetic access to chemically pure H/HS species (most typi-
cally with targets in the 4–8 length range22–34) has been critical to
advancing understanding of HS chemical and structural biology.
Syntheses of H/HS sequences, however, remains technically
challenging with typical requirements for lengthy routes. This,
combined with the inclusion of iduronate as the uronic acid in
many biologically-relevant H/HS oligosaccharides, has until
recently limited access to small scale, particularly for sequences
$8-mer. In addition to our own recent reports (vide infra) several
other syntheses of H/HS-related 10-mer and 12-mer oligosac-
charides have been described,13,35,36 whilst the recent develop-
ment of multi-enzymatic routes have also added to strategies for
access to the #12 length heparanome, oﬀering new potential
towards engineered H/HS targets.13,37
Longer H/HS sequences are involved in a number of
signicant interactions, some relevant to protein dimerization
implicit in signalling processes and central to regulation of
chemokine-mediated biology. The monomer–dimer equi-
libria, critical to regulating the biological eﬀects of inter-
leukin-8 (CXCL8), is believed to involve binding to HS
sequence(s) of >20 units.38 The natural occurrence of H/HS
across the longer heparanome (16–40-mers) almost certainly
means that a diversity of other critical biological interactions
involve longer sequence interactions. Viable synthetic access
to structurally-homogeneous longer H/HS sequences as
dened molecular tools would facilitate advancing our
understanding of unexplored GAG chemical biology of the
longer heparanome.
Synthetic access to the longer heparanome backbones has
been elusive. A review has reported a 16-mer39 and a dimeric
8-mer [equivalent to 16-mer] has been described40 whilst the
seminal work in addressing longer heparin-mimetics by
chemical synthesis remains the synthesis of a series of glucose-
based GAG mimetics up to the 20-mer,41 which, though
providing valuable tools to probe factor Xa/thrombin eﬀects, is
not a native H/HS sequence. Chemoenzymatic examples of a
mixed heparin-like 21-mer were also reported37 and examples of
the native-type longer heparin-like backbones beyond this, have
not hitherto been reported by chemical syntheses.
Recent advance in the area of less functionalized GAGs is
highlighted by a report on the synthesis of hyaluronic acid, a
simpler unsulfated GAG constituting a repeating GlcA-GlcNAc
unit, up to a 15-mer.1This journal is © The Royal Society of Chemistry 2015We recently described a scalable iduronate synthesis
facilitating multi-gram access to GlcN-IdoA disaccharides
suitable for oligosaccharide homologation,42 and synthesis of
several diﬀerent heparin-related oligosaccharides up to
12-mers. This included homogeneously fully 6-O-desulfated
12-mer on gram scale,43 and the rst synthetic per-6-O-sulfated
LMWH-like 12-mer.44 However, even scalable and eﬃcient
+[2]n iterations are likely to become limited in practicability
for access to substantively longer sequences due to pathway
length, separation convergence and possible cumulative
isomerism. We also therefore recently reported the synthesis
of a related heparin-like dodecasaccharide by replacing
disaccharide iteration with a GlcN-IdoA-GlcN-IdoA tetra-
saccharide block approach, exploiting the utility of iduronate
thioglycoside donor capability at the tetrasaccharide, rather
than disaccharide, level,45 to demonstrate a shorter 2-cycle
access to a dodecasaccharide target. The eﬃciency and
selectivity of these +[4]n iterations, coupled with our multi-
gram scale access to tetrasaccharide modules, suggested a
+[4]n block iteration strategy might provide a viable homolo-
gation to substantially longer GAG sequences, which have not
been addressable hitherto. Block synthesis has proven eﬀec-
tive in a number of elegant branched oligosaccharide
syntheses,46 but has not seen application to GAG oligosac-
charides above dodecasaccharides. Here we report an iterative
tetrasaccharide block chemical synthesis providing the rst
access to all the [4]n heparin-like [GlcN-IdoA]n backbone
oligosaccharides in the 20 to 40-mer range, which had previ-
ously eluded synthetic access. This more than doubles the
length of heparin-like oligosaccharides which have previously
been amenable to chemical synthesis, and also provides the
longest synthetic oligosaccharides (32-mer, 36-mer and
40-mer) of any type yet reported by solution or by solid-sup-
ported methods, exceeding the recent advance reported for
small scale provision of a uniform non-GAG 30-mer oligo-
mannoside,2 and the solution-phase 28-mer reported by
Fraser-Reid.47 Application of Pure-Shi HSQC NMR data
resolution enhancement is applied to conrm high anomeric
integrity and the rst chemical synthesis of a native heparin-
like NS, 2S-20-mer is also reported.
Results and discussion
Strategy
We sought to evaluate the use of a [GlcN-IdoA]2 tetrasaccharide
donor 1 45 for iterative homologation, proceeding from our
previously-described43 scalable 12-mer synthesis, to deliver the
rst examples of synthetic heparin-like oligosaccharide
sequences up to $20-mer (Fig. 1), ideally spanning the longer
native heparanome lengths.
It was also important to demonstrate that this route to
extended oligosaccharides could deliver usable quantities of
materials with reproducible homologation eﬃciencies and
anomeric integrity throughout the sequence. For all oligosac-
charide synthetic routes the reproducibility of coupling eﬃ-
ciency (and anomeric integrity) for longer chains is a recurrent
challenge. Similarly, convergence of separability of productChem. Sci., 2015, 6, 6158–6164 | 6159
Fig. 1 Strategy for iterative long heparin-like oligomer syntheses via tetrasaccharide 1 block homologation.
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View Article Onlinefrom incompletely glycosylated long acceptors presents diﬃ-
culties as the sequences become longer. We reasoned that
application of our block strategy could assist both aspects, by
signicantly reducing the number of sequential steps (fewer
glycosylations and decreasing cycles for any accumulating loss
of anomeric coupling integrity) and providing a more signi-
cant structural change upon each homologation step (thus
aiding separation and purication).Iterative synthesis of longest oligosaccharides
A coupling–deprotection cycle of two-step homologations using
donor tetrasaccharide 1 45 was envisioned for extending oligo-
saccharides from the dodecasaccharide level in a +4 iteration
sequence. Starting from O4-protected dodecasaccharide 2 43
selective release of O4 aﬀorded the starting dodecasaccharide
acceptor 3 in very high yield (Fig. 2). The subsequent homologa-
tions to 16-mer and thence to 20-mer proceeded in very good
overall yield (68% and 79% respectively) for each two-step
homologation. These steps could be performed on practicable
scale, providing 300 mg of this novel 20-mer. This is a signicant
scale of synthesis for any oligosaccharide intermediate even at
shorter lengths, and is essentially underpinned by ourmulti-gram
access to tetrasaccharide 1 resulting from scalable iduronate
synthesis.42,43With this eﬀective homologation to 20-mer in hand,
we then sought to evaluate further iterations. The glycosylations
of increasingly long acceptors using 1 proved reliable throughout
a further series of +[4] iterations aﬀording the 24-mer, 28-mer, 32-
mer, 36-mer and 40-mer. The homologations proceeded in high
yields both at the glycosylation and O4-deprotection steps (56–Fig. 2 Elongation from 12-mer 3 through to 40-mer 15. (i) MeOH, pyridi
97%; n ¼ 3: 8, 77%, 9, 95%; n ¼ 4: 10, 75%, 11, 93%; n ¼ 5: 12, 78%, 13, 9
6160 | Chem. Sci., 2015, 6, 6158–616478% yield over the two steps in each cycle, 8% overall for 13 steps)
and with high anomeric selectivity (Fig. 2).
To demonstrate that these syntheses could be performed on
usable scales, each of these homologations delivered 100–300
mg samples of protected oligosaccharides through the entire
16-mer to 32-mer series and at 30–76 mg scale for the 36-mer
and 40-mer. These are substantive scales for syntheses of
oligosaccharides of this type, and would be challenging even for
considerably shorter heparin-like sequences.
This series also compares favourably to the automated
chemical synthesis of the longest monosaccharide-based
oligosaccharide, which provides mg amounts of a partially
protected (non-GAG) oligomannoside.2 Purication of all long
heparins 4–15 by standard chromatography proved eﬀective,
employing our previously reported toluene/acetone solvent
system,43 also evidencing that the block approach assists the
viability of solution phase synthesis and purication by
greater substrate-product diﬀerentiations (ESI Fig. 74†). A
further aid to purication was the insolubility of longer
oligosaccharides in EtOAc/hexane mixtures, making precipi-
tation a reliable method to remove unwanted small molecule
traces from reactions.
This establishes a chemical synthesis of the longest synthetic
oligosaccharides of any structural type yet reported and also
signicantly increases the length of synthetic heparanoid
oligosaccharides now accessible by chemical synthesis. This
provides a paradigm-shi in planning access to the longer
heparanome by demonstrating an eﬀective solution-phase
strategy that can both span the entire target length range of
likely biological relevance and do so on viable scales.ne, (ii) NIS, AgOTf (cat.), DCM, 1. n ¼ 1: 4, 76%, 5, 90%; n ¼ 2: 6, 81%, 7,
3%; n ¼ 6: 14, 72%, 15, 87%, 16, 64%; n ¼ 7.
This journal is © The Royal Society of Chemistry 2015
Fig. 4 NUS Pure Shift HSQC spectra of dodecasaccharide 2. Overlay
of anomeric regions from standard HSQC (cross-peaks in red) vs. NUS
Pure Shift HSQC (cross-peaks in blue), allowing resolution of all 12
anomeric protons NUS Pure Shift HSQC expanded as inserts.
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View Article OnlineStructural characterization and sequence anomeric integrity
Mass spectral data for the series of oligosaccharides provided
convincing supporting data for structure, with molecular ions
present for [M + Na]+ as the base peak for all species, illus-
trated in Fig. 3 by base peaks for the series of longest oligo-
saccharides across the 24-mer, 28-mer, 32-mer and 36-mer
series (see also: ESI Fig. 39, 46, 53 and 58†), at this level of
oligomerization these fall within the macromolecule region
(9–13 kDa).
We wished to use NMR to conrm the anomeric integrity
across this series. Signicant resolution enhancement of the
twelve anomeric resonances for the 12-mer we reasoned may
then facilitate extrapolation to provide suﬃcient resolution
improvement for the longer series, important for dening
anomeric integrity in the longer sequence syntheses. NMR
conrmation of the purity of the nal products was attempted
prior to deprotection of the sugar hydroxyls, the protecting
aromatic groups providing extra dispersion through ring
current shis, and also low viscosity organic solvent (CDCl3)
resulting in faster correlation times and therefore sharper
linewidths.§ However, to record 2D spectra with suﬃcient
acquisition time in the indirect dimension to resolve all the
peaks would have taken a prohibitively long time, so non-
uniform sampling (NUS)48 of the indirect dimension of the
1H13C-HSQC spectra was employed. Resolution was improved
further by homonuclear decoupling during acquisition using a
BIRD pulse train49 (Fig. 4 and 5).
This provided dramatic enhancement to achieve suﬃcient
resolution of all twelve anomeric protons (Fig. 4). The signal to
noise ratio in the 2D-HSQC of the 1H13C-HSQC for dodeca-
saccharide 2 was 50 : 1 and as there is an absence of any
resonances arising from the other possible anomeric linkages
the stereoselectivity of the synthesis can thus be dened asFig. 3 MALDI mass spectra of protected long oligosaccharides. (a) 24-
mer, 9. (b) 28-mer, 11. (c) 32-mer, 13. (d) 36-mer, 14.
Fig. 5 NUS HSQC 800 MHz data for long oligosaccharides: (a) 16-
mer, 4. (b) 36-mer, 14. Inset expansions.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 6158–6164 | 6161
Fig. 7 Nano-electrospray mass spectral data for icosasaccharide
[GlcNH2-IdoA2S]10-OMe 18. (a) Main ions observed for z ¼ 7 (27%), 8
(72%), 9 (100%) and 10 (41%). (b) Observed and theoretical isotope
patterns for major ion [M  9H]9 (LTQ Oribitrap XL).
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View Article Onlinebetter than 98% (Fig. 4; ESI Fig. 55–57†). In the longer oligomers
>12-mer, the similarity in chemical environment in the central
units results in little dispersion of those additional anomeric
resonances, which precludes further resolution by NMR, but the
crosspeak intensities for these atoms scale consistently with the
number of monomers in each oligomer (ESI Fig. 57b†).
Furthermore, there are evidently no novel cross peaks in the
HSQC spectra of the longer oligomers, supporting the extrapo-
lation and indicating a very high level of anomeric delity
(Fig. 5).
Accessing synthetic 2-O-sulfated and 2-O,N-sulfated 20-mers
To illustrate access to sulfated, biologically-relevant, long
heparanoid systems we selected fully protected icosa-
saccharide 6 to evaluate conversion to the native heparin-type
N- and 2-O-sulfated 20-mer 19 (Fig. 6) via 20-mer 18. The eﬃ-
ciency of the polysulfation steps and purication of longer
sulfated structures are oen challenging in H/HS syntheses.
Gratifyingly, 20-mer 6 (40 mg) was saponied, O-sulfated and
hydrogenated43–45 in 38% overall yield for three steps to aﬀord
2-O-sulfated, N- and 6-O-desulfated icosasaccharide amine
(A4I2-[A0I2]9)-OMe50 18 (Fig. 6). This material was character-
ized using nanoelectrospray MS (Fig. 7), which showed
multiple signals for diﬀerent charge states of the expected
parent ion, along with matching isotope patterns, fully
consistent with successful installation of all O-sulfate groups.
Additionally, 800 MHz NMR spectra conrmed complete
hydrogenolysis of benzyl protecting groups and reduction of
azides to deliver the structurally homogenous 18 (see ESI
Fig. 64–66†).
The O-2-sulfated icosasaccharide (A4I2-[A0I2]9)-OMe 18 was
then N-sulfated to provide the IdoA 2-O- and glucosamine
N-sulfated (S4I2-[S0I2]9)-OMe 20-mer 19 in 93% yield. Shi of
H2 signals conrm no remaining NH2 sites (Fig. 8) with two H2
NS signals appearing for 19, and that the minor of which
equates to approximately one residue was conrmed by COSY
and HSQC data (ESI Fig. 70†). This is the rst syntheticFig. 6 Deprotection and sulfation to aﬀord homogeneous heparin-like 20
(i) LiOH, THF/MeOH/H2O, 48%. (ii) NMe3cSO3, DMF, mW,44 90%. (iii) Pd(O
6162 | Chem. Sci., 2015, 6, 6158–6164heparin-like material of this length reported. The eﬃciency
and completeness of the N-sulfation was conrmed by 800
MHz NMR (Fig. 8 and ESI Fig. 70–72†) evidenced by the
denitive shi of the H2 signals for the GlcN rings. PAGE
analysis showed close comparison to commercial digest
heparin dp20, but with higher purity (ESI Fig. 73†). Such a
process provides, for the rst time, a synthetic access to two
homogeneous 20-mer HS-like oligosaccharides of diﬀering
native-like sulfation levels, redening the boundaries for a
solution phase approach to native HS systems.-mers [GlcNH2-IdoA2S]10-OMe, 18 and [Glc6SNS-IdoA2S]10-OMe, 19.
H)2/C, EtOH/H2O, H2, 89%. (iv) Pyridine SO3 complex, H2O.
This journal is © The Royal Society of Chemistry 2015
Fig. 8 NMR analysis of GlcN N-sulfation of icosasaccharide (A4I2-
[A0I2]9)-OMe 18 to icosasaccharide (S4I2-[S0I2]9)-OMe 19. Overlay
spectra for 18 (blue) and 19 (red), show coincidence of terminal
methoxy resonances, and deﬁnitive shift of H2 signals due to N-2-
sulfation in 19. Resolved single GlcNS marked by blue arrow (see ESI
Fig. S70†).
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View Article OnlineConclusions
The rst purely synthetic chemical approach to provide native-
backbone heparin-like oligosaccharides in the longer hepar-
anome (>16-mer) is reported. This demonstrates that a tetra-
saccharide block-wise iterative approach enables syntheses up
to and including the longest synthetic oligosaccharide (of any
type) yet described (40-mer). This now facilitates chemical
synthesis to this previously inaccessible area of glycospace with
sequence homogeneity. This work shows that adapting solution
phase synthesis using block-synthetic modules can provide a
practicable route to long saccharides of high purity and
stereochemical integrity. This report also describes the chem-
ical synthesis of a pure heparin-like N,O-2-sulfated icosa-
saccharide (20-mer) which has signicance for the current
importance of developing pure synthetic heparin-type replace-
ments. Additionally, this report describes an important advance
in NMR structural assignment at 12-mer level and quantica-
tion of anomeric integrity in long oligosaccharides. NUS Pure-
Shi HSQC is shown to provide very dramatic resolution
enhancement and was applied to (i) provide the rst clear
resolution of the 12 anomeric signals for a synthetic heparin-
related dodecasaccharide and (ii) thereby allowed comparative
data up to a synthetic 36-mer providing direct, robust NMR
support regarding the anomeric integrity in these very long
synthetic oligosaccharides. This will have value for the analysis
of other long synthetic oligosaccharide systems.Acknowledgements
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